Insulin-sensitizing NE3107 in Improving Sleep and Fatigue in Subjects With Traumatic Brain Injury
Open Label Phase IIa Study Evaluating the Safety and Efficacy of NE3107 in Improving Sleep and Fatigue in Subjects With Traumatic Brain Injury
Sponsor: BioVie Inc.
Terminated
The study team was informed by the final participant's PCP that the subject discontinued the study medication. The participant's caregiver requested for the participant to be withdrawn from the study. The investigator has decided to close out.
Other terminated trials from BioVie Inc.
More terminations from BioVie Inc.
Other Traumatic Brain Injury trials with similar outcome
Listed as NCT05970575, this PHASE2 trial focuses on Traumatic Brain Injury and remains terminated or withdrawn. Sponsored by BioVie Inc., it has been updated 5 times since 2023, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
5 versions recorded-
Aug 2025 — Present [monthly]
Terminated PHASE2
Status: Recruiting → Terminated
-
Sep 2024 — Aug 2025 [monthly]
Recruiting PHASE2
-
Aug 2024 — Sep 2024 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jul 2024 — Aug 2024 [monthly]
Not Yet Recruiting PHASE2
-
Sep 2023 — Jul 2024 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- BioVie Inc.
- Neurological Associates of West Los Angeles
For direct contact, visit the study record on ClinicalTrials.gov .